G2B Pharma Receives Project Financing From Sosei and Right to In-license Nasal Delivery Technologies From SNBL
13 août 2014 03h01 HE
|
G2B Pharma Inc.
SAN FRANCISCO, Aug. 13, 2014 (GLOBE NEWSWIRE) -- G2B Pharma Inc. ('G2B' Chairman and CEO, Nigel Ten Fleming PhD, San Francisco, USA) announces the signing of an agreement with Sosei Group...
Novel Nasal Epinephrine Shows Comparable Absorption to EpiPen(R) in a Feasibility Study
10 sept. 2013 09h30 HE
|
G2B Pharma Inc.
SAN FRANCISCO, Sept. 10, 2013 (GLOBE NEWSWIRE) -- Shin Nippon Biomedical Laboratories, Ltd. ('SNBL' Chairman and CEO, Ryoichi Nagata MD PhD FFPM, Tokyo, Japan) and G2B Pharma Inc. ('G2B' Chairman and...